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TTR (transthyretin) was found recently to possess proteolytic
competency besides its well-known transport capabilities. It was
described as a cryptic serine peptidase cleaving multiple natural
substrates (including β-amyloid and apolipoprotein A-I) involved
in diseases such as Alzheimer’s disease and atherosclerosis. In
the present study, we aimed to elucidate the catalytic machinery
of TTR. All attempts to identify a catalytic serine residue were
unsuccessful. However, metal chelators abolished TTR activity.
Proteolytic inhibition by EDTA or 1,10-phenanthroline could be
reversed with Zn2 + and Mn2 + . These observations, supported
by analysis of three-dimensional structures of TTR complexed
with Zn2 + , led to the hypothesis that TTR is a metallopeptidase.
Site-directed mutagenesis of selected amino acids unambiguously
confirmed this hypothesis. The TTR active site is inducible and
constituted via a protein rearrangement resulting in ∼7% of
proteolytically active TTR at pH 7.4. The side chain of His88
is shifted near His90 and Glu92 establishing a Zn2 + -chelating
pattern HXHXE not found previously in any metallopeptidase
and only conserved in TTR of humans and some other primates.
Point mutations of these three residues yielded proteins devoid
of proteolytic activity. Glu72 was identified as the general base
involved in activation of the catalytic water. Our results unveil
TTR as a metallopeptidase and define its catalytic machinery.
Key words: apolipoprotein A-I, amyloid-β peptide, metallopepti-
dase, transthyretin, zinc.
INTRODUCTION
TTR (transthyretin) is a plasma protein existing mainly as
a homotetramer [1]. TTR is well characterized, since point
mutations can cause FAP (familial amyloid polyneuropathy) [2],
a lethal neurodegenerative disorder hallmarked by deposition
of TTR amyloid fibrils [3]. A myriad of crystal structures of
human wtTTR (wild-type TTR) are available from the PDB [4].
Backbone hydrogen bonds between TTR monomers favour dimer
formation, whereas dimers interact predominantly via amino acid
side chains to form a tetramer. TTR stability depends on intact
quaternary and tertiary structure, with partial unfolding initiating
misassembled aggregates [5]. The presence of metal ions [6],
covalent modification of Cys10 [7], lowered pH [8] or point
mutations [9] can destabilize the tetrameric TTR structure and
favour protein rearrangement.
TTR is the transporter of T4 (thyroxine) and retinol owing
to its association with RBP (retinol-binding protein) [10] in
a 1:1 molar ratio in vivo [11], an interaction that stabilizes
TTR more than 15-fold [12]. Besides interacting with T4 and
RBP, approximately 1–2% of total plasma TTR is associated
with HDL (high-density lipoproteins), through binding to apoA-I
(apolipoprotein A-I) [13]. In-depth analysis of the interaction of
TTR with apoA-I revealed the latter to be a peptidase substrate
of TTR [14]. TTR is currently described as a peptidase of unknown
type (U9G.071) in the MEROPS database [15]. Initial studies
suggested TTR to be a serine peptidase [14] given that it cleaves
apoA-I after a phenylalanine residue at an optimal pH of 7
and that it is apparently inhibited by very high concentrations
of serine peptidase inhibitors [14]. Although binding of small
compounds such as T4 has no effect on the peptidase activity
of TTR, interaction with RBP completely abolishes substrate
cleavage [14]. To date, a significant number of natural substrates
of TTR have been identified such as apoA-I, NPY (neuropeptide
Y) and Aβ (amyloid β-peptide) [14,16,17].
ApoA-I is the main protein component of HDL and is crucial
for reverse cholesterol transport [18]. Limited proteolysis has
demonstrated the vulnerability of the C-terminus of apoA-I
in lipid-poor particles, whereas the lipid-bound protein is
protected from cleavage [18]. The apoA-I N-terminus appears
to be important for stabilizing the lipid-free monomeric structure,
whereas the C-terminus is required for interactions with other
proteins and lipids [19]. After apoA-I cleavage by TTR, HDL
particles display a reduced capacity to promote cholesterol efflux,
and truncated apoA-I displays increased amyloidogenicity [20],
suggesting that TTR might have an impact on the development
of atherosclerosis. In the case of Aβ, cleavage by TTR has only
been demonstrated in vitro [17], and suggested to be a protective
mechanism preventing Alzheimer’s disease [17].
Despite the availability of a large number of wtTTR and
mutated TTR X-ray structures crystallized at pH 7–8, the catalytic
mechanism of TTR is still unknown. In the present study,
we establish TTR as a metallopeptidase and uncover multiple
catalytic residues indispensable for proteolytic activity.
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EXPERIMENTAL
Protein production
Recombinant wtTTR and TTR mutants were produced in BL-21
pLys Escherichia coli cells transformed with pETF1 carrying
TTR cDNA [21]. Proteins were isolated and purified as described
in [14]. Briefly, after bacterial lysis, protein extracts were run
on DEAE-cellulose (Whatman) ion-exchange chromatography,
dialysed, freeze-dried and isolated in native Prosieve® agarose
(FMC) gels. After electrophoresis, the TTR band was excised
and electroeluted in a Elutrap® system (Schleicher and Schuell)
in 38 mM glycine and 5 mM Tris/HCl (pH 8.3) overnight at
50 V (4 ◦C). Finally, the protein was dialysed in 50 mM Tris/HCl
(pH 7.5). Protein quantification was performed using Lowry-
based DC Protein Assay (Bio-Rad Laboratories), following the
manufacturer’s protocol. The TTR molar concentration was
always calculated assuming the exclusive presence of the
tetrameric species.
Site-directed mutagenesis
The TTR cDNA cloned into the pETF1 vector was used to produce
TTR mutants (using the QuikChange® kit; Stratagene). Mutants
were constructed using two mismatched primers, introducing a
base substitution in the original sequence. Minipreps of plasmid
DNA were tested by sequencing at SeqLab (Go¨ttingen, Germany).
After protein production, mutations were confirmed by MALDI
(matrix-assisted laser-desorption ionization)-MS of either the
full-length protein or of the trypsin-digested TTR peptides
(Supplementary Table S1 at http://www.BiochemJ.org/bj/
443/bj4430769add.htm), at the Proteomics Unit, Institute of
Molecular Pathology and Immunology at the University of Porto,
Porto, Portugal.
Kinetic assays
TTR proteolytic activity was tested with the fluorigenic peptide
Abz-YGGRASDQ-EDDnp [where Abz is o-aminobenzoyl and
EDDnp is N-(2,4-dinitrophenyl)-ethylenediamine]. This substrate
was found when screening a library of fluorigenic peptides [22].
Turnover of Abz-YGGRASDQ-EDDnp by TTR is approximately
20-fold higher (kcat/Km = 408.8 s− 1 · M− 1) when compared with
Abz-ESFKVS-EDDnp (kcat/Km = 17.5 s− 1 · M− 1), an apoA-I
sequence encompassing the TTR cleavage site. Hydrolysis of
Abz-YGGRASDQ-EDDnp at 37 ◦C in 50 mM Tris/HCl (pH 7.5)
was followed by measuring the fluorescence at λem 420 nm and
λex 320 nm in an Fmax plate reader (Molecular Devices) for
30 min. Specificity rate constants (kcat/Km) were determined under
pseudo-first-order conditions [23]. TTR (5 μM total protein)
was added to the substrate (tested at 5 μM and 10 μM) in a
final volume of 100 ml of reaction buffer (50 mM Tris/HCl,
pH 7.5). Reactions were monitored for 30 min and pseudo-first-
order rate constants were obtained from linear plots where the
y-axis corresponds to ln[(Fmax − Ftime)/Fmax], where Fmax is
the fluorescence corresponding to total degradation of 5 μM or
10 μM substrate and Ftime is the fluorescence measured at each
time point, and the x-axis corresponds to the time of reaction.
The slope of the linear plots, corresponding to the first-order
rate constants, was divided by the total protein concentration
to provide kcat/Km. Determination of the concentration of active
enzyme in the TTR preparation was performed by titration
with an irreversible phosphonate inhibitor that completely blocks
TTR activity at 1 μM [16]. Active-site titration was carried out
with inhibitor concentrations ranging from 0.01 to 1 μM. After
enzyme/inhibitor incubation for 30 min at 37 ◦C, activity was
monitored as described above. Concentration of active enzyme
was determined from the x-axis intercept in the linear range of the
plot of residual activity as a function of inhibitor concentration
[24].
Chemical modification of TTR with serine peptidase inhibitors
TTR (5 μM) was incubated with each of the following
peptidase inhibitors: Pefabloc SC (4 mM; Roche), DFP
(di-isopropylfluorophosphate) (100 μM; Calbiochem), TPCK
(tosylphenylalanylchloromethane) (100 μM; Roche) and PMSF
(1 mM; Sigma). After 30 min of incubation at 37 ◦C, reaction
mixtures were separated by SDS/PAGE (15% gel) and stained
with Coomassie Blue. MALDI-MS of trypsin-digested gel bands
corresponding to modified TTR was performed at the Protein
Core Facility, Columbia University, New York, NY, U.S.A., as
described in [14]. For chemical modification of apoA-I (1.7 μM)
with PMSF, the protein was incubated with 1 mM inhibitor for
30 min at 37 ◦C. After SDS/PAGE, MALDI-MS was performed
at the Proteomics Unit, Institute of Molecular Pathology and
Immunology at the University of Porto, Porto, Portugal.
Inhibition of TTR cleavage of fluorigenic peptides
For analysis of inhibition of TTR proteolytic activity using
Abz-YGGRASDQ-EDDnp as substrate, TTR (5 μM) was
pre-incubated for 30 min at 37 ◦C in reaction buffer with
the following inhibitors: 1–10 mM EDTA (Merck), 10 μM
E-64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane]
(Roche), 10 μM phosphoramidon (Roche), 10 μM bestatin
(Sigma), 0.3 μM aprotinin (Sigma), 100 μM TPCK (Roche),
100 μM TLCK (tosyl-lysylchloromethane) (Roche), 100 μM
chymostatin (Sigma), 100 μM leupeptin (Sigma), 1 mM PMSF
(Sigma), 1 μM pepstatin (Sigma), 1 mM 1,10-phenanthroline
(Roche) and 1 mM 1,7-phenanthroline (Alfa Aesar). After
enzyme/inhibitor incubation, 5 μM Abz-YGGRASDQ-EDDnp
was added and activity was monitored as described above.
Relative fluorescence was converted into percentages of residual
activity relative to uninhibited controls. To analyse the effect
of addition of divalent metals to TTR inhibited with either
1,10-phenanthroline or EDTA, TTR was pre-incubated with the
inhibitor (as described above) and then increasing concentrations
of metals were added to the reaction and proteolytic activity was
determined. In the experiments with CaCl2 addition, reactivation
of TTR with Zn2 + was tested in the presence of 1 mM CaCl2.
The apo-enzyme form of TTR was obtained by dialysis of TTR
pre-incubated with 10 mM EDTA. Control measurements of
the reactions where no TTR was added were performed, and the
results obtained were subtracted from the results from reactions
containing the peptidase.
TTR proteolysis assay using full-length apoA-I as substrate
ApoA-I digestion by TTR was performed as described previously
[14]. Briefly, 2 mg of TTR was incubated with 1 mg of apoA-I
in 50 mM Tris/HCl (pH 7.5) at 37 ◦C overnight. The inhibitory
effect of EDTA was tested by the addition of 10 mM or 50 mM
EDTA to TTR, before addition of apoA-I. After incubation for
30 min at 37 ◦C, apoA-I was added and reactions proceeded
at 37 ◦C overnight. Reaction mixtures were subsequently
separated by SDS/PAGE (15% gel) and visualized by silver
staining.
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Determination of Zn2+ levels in TTR
The Zn2 + concentration in TTR samples was measured at the
Chemical Speciation and Bioavailability Laboratory, Center of
Marine and Environmental Research, University of Porto, Porto,
Portugal, as described previously [25]. Briefly, 3.2 mg of TTR was
diluted in Zn2 + -free double-distilled water and total Zn2 + content
was determined by atomic absorption spectrophotometry with
flame atomization (PU 9200X, Philips). For Zn2 + quantification,
a calibration curve was created using Zn2 + standards. For
Zn2 + quantification in TTR treated with EDTA, the protein
was incubated with 10 mM EDTA for 30 min at 37 ◦C and
thereafter the chelator was removed by dialysis against 50 mM
Tris/HCl (pH 7.5). For measurement of Mn2 + , Fe2 + and Co2 +
concentrations, the same protocol was followed.
Thioflavin-T-binding assay
For the thioflavin-T-binding assay, 100 μg of purified TTR was
incubated in 50 mM sodium acetate (pH 4) for 72 h at room
temperature (22 ◦C) in a final volume of 200 μl. For aggregation
assays with 10 mM EDTA, 1 mM 1,10-phenanthroline or Zn2 + ,
TTR was incubated with one of these compounds for 30 min at
37 ◦C and subsequently thioflavin-T was added at a concentration
of 30 μM in 50 mM glycine (pH 9). The excitation spectra
from 400 to 500 nm were recorded on a Horiba Fluoromax-
4 spectrofluorimeter at 19 ◦C. The intensity of fluorescence at
451 nm, which is the characteristic maximum for thioflavin-T
bound to aggregated fibrils, was subtracted from the intensity of
fluorescence at 451 nm of the control without TTR. Results are
presented as a percentage relative to the value obtained for wtTTR.
Each assay was performed in triplicate.
Size-exclusion chromatography
Size-exclusion chromatography experiments were performed
with a pre-packed Superose 12 10/300 GL column (GE
Healthcare). The column was equilibrated with 150 mM NaCl
and 50 mM Tris/HCl (pH 7.5) and a 0.5 ml/min flow rate
was used throughout the experiments. A total of 150 μg of
purified TTR was used in each run. Protein elution was
monitored by measuring the absorbance at 280 nm. Calibration
was carried out using the following protein standards (Stokes
radius, elution volume): catalase (5.22 nm, 11.03 ml), aldolase
(4.81 nm, 11.26 ml), albumin (3.55 nm, 11.76 ml), ovalbumin
(3.05 nm, 12.66 ml), chymotrypsinogen (2.09 nm, 14.66 ml)
and ribonuclease (1.64 nm, 15.14 ml). The void volume was
determined to be 7.21 ml using Blue Dextran 2000. The
Kav parameter was determined according to the equation
Kav = (V e − V0)/(V t − V0), where V e represents the elution
volume, V0 is the void volume of the column, and V t is the total
bed volume. The Stokes radius (Rs) for the experimental data was
calculated by interpolation using: ( − logKav)1/2 = f(Rs).
Data analysis
All assays were performed at least twice with each dataset in
duplicate. Results are means +− S.D.
RESULTS
TTR is not a serine peptidase
TTR has been suggested to be a cryptic serine peptidase [14].
Serine peptidases are hallmarked by an activated nucleophilic
serine [15], an oxyanion hole and a substrate-binding cleft. After
an in-depth analysis of multiple X-ray structures of monomeric,
dimeric and tetrameric TTR, Ser46, Ser77 and Ser85 were selected
as putative candidates that could act as activated nucleophiles. We
mutated each of these three serine residues to glycine or alanine
and confirmed the respective mutations by tryptic MS (results not
shown). All three mutants retained proteolytic activity (results
not shown), suggesting that TTR is not a serine-like peptidase.
Ser8, Ser23, Ser50, Ser52, Ser100 and Ser117 of TTR, although they
were very unlikely to be active-site candidates, were also mutated.
All of these mutants retained proteolytic activity (results not
shown). The only TTR serine residues that were not mutated
were Ser112 and Ser115 as these are located in the hydrophobic
central channel of TTR, described previously to be irrelevant for
TTR activity [14].
As TTR was suggested to be a serine-like peptidase on the
basis of the inhibition of apoA-I cleavage by high concentrations
of serine peptidase inhibitors [14], the effect of these compounds
was re-examined in detail using full-length apoA-I as substrate.
MS analysis of TTR incubated with the covalent binding
serine peptidase inhibitor Pefabloc SC revealed the presence of
multiple modified TTR peptides (Supplementary Table S2 at
http://www.BiochemJ.org/bj/443/bj4430769add.htm), indicating
that highly concentrated Pefabloc SC modifies TTR unspe-
cifically, therefore affecting peptidase activity in a non-specific
manner. For TTR incubated with PMSF, DFP and TPCK, no
modification of TTR was found (results not shown). However,
PMSF was able to modify the substrate (apoA-I) and generate
an aberrant PMSF adduct of a peptide consisting of amino
acids 227–238 of apoA-I (1540.86 Da) (Supplementary Table S3
at http://www.BiochemJ.org/bj/443/bj4430769add.htm). PMSF
modification of the substrate is most likely to be the reason
for reduced apoA-I cleavage by TTR. Besides inhibition of
TTR activity by serine peptidase inhibitors, we previously
observed inhibition of TTR activity with peptide phosphonate
inhibitors when using the fluorigenic apoA-I peptide substrate
[16]. Phosphonate inhibitors are able to block serine peptidases,
but some members of this class of compound are known to
be effective inhibitors of metallopeptidases [26]. Combined,
the absence of catalytic serine residues in TTR and unspecific
modifications of TTR and apoA-I by peptidase inhibitors reveal
that TTR is not a serine peptidase.
TTR proteolytic activity depends on metal ions and is inhibited by
metal chelators
A highly reproducible assay using fluorigenic peptide substrates
was set up to investigate the action of multiple prototypic
peptidase inhibitors on TTR activity (Figure 1a). As we
previously observed interference with proteolytic activity by post-
translational modifications of Cys10 in TTR [16], all assays were
performed with a C10A mutant which was equipotent to wtTTR
(Table 1). Only two well known metallopeptidase inhibitors,
EDTA and 1,10-phenanthroline, could abolish TTR proteolytic
activity (Figure 1a). Interestingly, 1,7-phenanthroline, an isomeric
non-chelating analogue of 1,10-phenanthroline, achieved only
minor inhibition (Figure 1a). These results were corroborated
with a second substrate mimicking the TTR cleavage site
in apoA-I [14] (Figure 1b). Moreover, when using full-length
apoA-I as substrate, when increasing amounts of EDTA are
used, full inhibition is also achieved (Supplementary Figure
S1 at http://www.BiochemJ.org/bj/443/bj4430769add.htm). The
same inhibition profile was observed when wtTTR was used,
proving that inhibition by EDTA and 1,10-phenanthroline is not
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Figure 1 TTR cleavage of fluorigenic peptides is inhibited by EDTA and
1,10-phenanthroline
(a) TTR was pre-incubated with different peptidase inhibitors before cleavage of Abz-
YGGRASDQ-EDDnp was determined. *P < 0.0005. (b) TTR cleavage of Abz-ESFKVS-EDDnp
(mimicking apoA-I cleavage site) after pre-incubation with different peptidase inhibitors.
*P < 0.001. Relative fluorescence values were converted into percentages of residual activity
relative to uninhibited controls. Each experiment was performed twice in duplicate.
dependent on the point mutation C10A (Supplementary Figure
S2 at http://www.BiochemJ.org/bj/443/bj4430769add.htm).
EDTA inhibited TTR in a dose-dependent manner (Figure 2a).
Excess amounts of EDTA had to be scavenged with 1 mM Ca2 +
ions before addition of Zn2 + could surmount inhibition and
restore full TTR proteolytic activity (Figure 2b). Alternatively,
excessive EDTA could be removed via dialysis, yielding an
inactive apo-enzyme that can be reactivated by addition of
Zn2 + (Figure 2c). This indicates that the Zn2 + -scavenging effect
of EDTA leads to proteolytic inactivation of TTR. Similar
results were obtained with wtTTR (Supplementary Figure S3 at
http://www.BiochemJ.org/bj/443/bj4430769add.htm).
Complete inhibition of TTR with 1 mM 1,10-phenanthroline
could be partially reversed by adding Zn2 + (Figure 2d). Zn2 +
at 250 μM restored 36% of proteolytic activity in the presence
of inhibitor. This finding is similar to the results obtained
Table 1 Specificity rate constants (k cat/Km) of different TTR mutants
Each individual mutant was tested at least three times in quadruplicates. Results are
means +− S.D. *P < 0.001, **P < 0.0005 compared with wtTTR.
Protein k cat/K m (s− 1 · M− 1)
wtTTR 408.8 +− 6.3
TTR C10A 367.0 +− 20.5
TTR C10A/H88A 3.5 +− 1.8**
TTR C10A/H90A 1.5 +− 0.3**
TTR C10A/E92A 8.7 +− 4.8**
TTR C10A/E72A 3.7 +− 1.2**
TTR C10A/E89A 76.2 +− 14.8**
TTR C10A/H31G 4.8 +− 0.2**
TTR C10A/K70A 4.2 +− 2.3**
TTR C10A/D74A 168.2 +− 36.0*
with EDTA where the addition of 250 μM Zn2 + restored
43% activity (Figure 2b). Zn2 + concentrations exceeding an
optimal value (250 μM for TTR) inhibited TTR (results not
shown), as described previously for other metallopeptidases [27].
Nevertheless, after inhibition of TTR with 1,10-phenanthroline,
dialysis yielded an active peptidase instead of an inactive apo-
enzyme (results not shown). This effect was described previously
for carboxypeptidase A where inhibition of the enzyme with 1,10-
phenanthroline was reversed by Zn2 + addition, but dialysis of
the enzyme treated with the metal chelator restored the active
enzyme rather than producing the apo-enzyme. In that case, it
was suggested that dialysis leads to dissociation of the Zn2 +
–1,10-phenanthroline complex permitting the re-incorporation of
the Zn2 + ion in the enzyme [28]. Addition of 1 mM CaCl2 did not
sequester 1,10-phenanthroline as observed previously for EDTA,
since binding of 1,10-phenanthroline to Ca2 + is significantly less
strong [29] (Figure 2e). In summary, these results indicate that
Zn2 + plays a crucial role in the proteolytic activity of TTR and
thereby suggest that TTR is a Zn2 + -dependent metallopeptidase.
TTR is reactivated by other divalent metal ions
The active site necessary for proteolytic activity has never
been observed in any X-ray structure of wtTTR obtained at
physiologically relevant pH (pH 7–8). This triggered the question
of whether this might be due to an incorrect metal being
present in crystallization assays. Zn2 + is typically found in the
active site of metallopeptidases, but Co2 + , Cu2 + , Ni2 + , Mn2 + or
Fe2 + can also produce active metallopeptidases as described for
metalloenzymes such as thermolysin [30] or peptide deformylase
[31]. Interestingly, TTR complexed to Mn2 + was even slightly
more active than its Zn2 + analogue (Figure 3a), indicating that
TTR can be active with metals other than Zn2 + in vitro. Further
metals tested (Fe2 + and Co2 + ) also yielded active enzymes
(Figures 3b and 3c), whereas in the presence of Ni2 + or Cu2 + ,
TTR displayed very little proteolytic activity (Supplementary
Figures S4a and S4b respectively at http://www.BiochemJ.
org/bj/443/bj4430769add.htm).
Only a fraction of TTR contains Zn2+ and is proteolytically
competent
Metallopeptidases require a metal ion to correctly locate and
activate a water molecule [15]. The metal ion is often Zn2 +
co-ordinated by three residues of the enzyme and a water
molecule. Such a structural feature could not be found in any
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Figure 2 TTR inhibition by EDTA and 1,10-phenanthroline is reversed by addition of ZnCl2
(a) TTR activity was assessed after pre-incubation with increasing concentrations of EDTA. (b) TTR proteolytic activity was blocked with 1 mM EDTA. Reactivation of TTR with Zn2 + was tested in
either the presence or the absence of 1 mM CaCl2. (c) After dialysis, TTR inhibited by EDTA can be reactivated by Zn2 + . TTR was inhibited with 10 mM EDTA, dialysed and subsequently reactivated
with increasing concentrations of Zn2 + . (d) TTR was incubated with 1 mM 1,10-phenanthroline before activity was tested in the presence of increasing concentrations of Zn2 + . Addition of ZnCl2
to TTR inhibited by 1,10-phenanthroline (1,10-phen) partially restored proteolytic activity. (e) CaCl2 does not affect Zn2 + reactivation of TTR inhibited with 1,10-phenanthroline. TTR proteolytic
activity was blocked with 1 mM 1,10-phenanthroline (1,10-phen). Reactivation of TTR with 250 μM Zn2 + was tested either in presence or absence of 1 mM CaCl2. Each experiment was performed
at least twice in duplicate. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 3 TTR inhibited by 1,10-phenanthroline is reactivated by divalent
metal ions
TTR was incubated with 1 mM 1,10-phenanthroline (1,10-phen) before activity was tested in the
presence of increasing concentrations of Mn2 + (a), Co2 + (b) or Fe2 + (c). Each experiment
was performed at least twice in duplicate. **P < 0.01, ***P < 0.001.
wtTTR X-ray structure in the PDB crystallized in the pH
range 7–8. Recently, several structures of TTR double mutants
(F87M/L110M) crystallized in the pH range 4.5–7.5 comprising
multiple Zn2 + -binding sites were described [32]. In one of these
structures, a large reorganization of amino acids 74–90 occurs,
shifting the side chain of His88 by almost 9 Å (1 Å = 0.1 nm)
such that this residue together with His90 and Glu92 co-ordinates
a Zn2 + (e.g. PDB code 3GRG) [32]. These three relocated amino
acids, comprising two neutral (His88 and His90) and one negatively
charged amino acid (Glu92), are reminiscent of active sites in
metallopeptidases.
To determine whether recombinant TTR contains Zn2 + ,
the concentration of this ion in wtTTR preparations was
measured using atomic absorption spectrophotometry with
flame atomization. In 5 μM wtTTR, a Zn2 + concentration
of approximately 1 μM could be measured. Moreover, when
TTR was pre-treated with EDTA before atomic absorption
spectrophotometry, no Zn2 + was detected. As described above,
metals other than Zn2 + were shown to interfere with TTR
proteolytic activity, as is the case for Mn2 + , Fe2 + and
Co2 + ; however, these metals were not detected in the wtTTR
preparations (results not shown).
We analysed the effect of adding Zn2 + directly to recombinant
TTR. Increasing Zn2 + concentrations did not increase proteolytic
activity further, but inhibited it (Figure 4a). Such an effect can
be explained by Zn2 + binding near the active site, as observed
previously in X-ray structures of other metallopeptidases [33].
Such a second Zn2 + -binding site is observed in one of the
analysed TTR X-ray structures [32]. One of its residues, Asp74,
was mutated, but this mutation did not abolish the inhibitory
effect of excessive Zn2 + (Figure 4a). The presence of metal ions
can destabilize the TTR tetrameric structure [6]. To check whether
the inhibitory effect of increasing Zn2 + concentrations on TTR
proteolytic activity was related to an increased TTR aggregation
induced by the metal, we performed thioflavin-T-binding assays
of TTR in the presence of 100 and 250 μM Zn2 + . We observed
that Zn2 + addition did not increase TTR aggregation (Figure 4b).
The molar ratio of TTR and Zn2 + determined in our prepara-
tions (∼5:1 TTR/Zn2 + ) suggested that not all recombinant TTR
is in a proteolytically active state. We therefore determined the
percentage of proteolytically active wtTTR by active-site titration
of a 5 μM TTR solution at pH 7.5 with a strong phosphonate
inhibitor identified previously [16] (Supplementary Figure S5
at http://www.BiochemJ.org/bj/443/bj4430769add.htm), which
labels the enzyme active site by co-ordinating the catalytic Zn2 +
[26]. Surprisingly, only a minor fraction of 340 nM wtTTR (∼7%
of total wtTTR) was in a proteolytically active state (Figure 4c).
This percentage was lower than what was expected given the
TTR/Zn2 + molar ratio. This result indicates that only a minor
amount of wtTTR has proteolytic competence at physiological
pH.
TTR is a metallopeptidase with an inducible Zn2+ -binding site
On the basis of the above results, we hypothesized that TTR
is a metallopeptidase having His88, His90 and Glu92 as the three
relevant residues binding the catalytic Zn2 + . To confirm this
hypothesis, mutants of each of the above residues to alanine
were generated, and their kinetic parameters were determined
(Table 1). Mutating any of these three residues led to inactive
TTR (Table 1), demonstrating that His88, His90 and Glu92 are the
active-site residues.
In metallopeptidases, a reactive hydroxyl ion is generated by
transferring a proton from the catalytic water to a neighbouring
c© The Authors Journal compilation c© 2012 Biochemical Society
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Figure 4 Only a small fraction of TTR comprises Zn2+ and is proteolytically
competent
(a) Proteolytic activity of either TTR C10A or TTR C10A/D74A was tested in the presence of
increasing concentrations of ZnCl2. Both TTR mutants were inhibited by addition of excessive
amounts of ZnCl2. The statistic analysis was performed relatively to each respective mutant
without ZnCl2 addition. *P < 0.05, **P < 0.01, ***P < 0.001. (b) Aggregation of TTR in the
absence and presence of different Zn2 + concentrations as determined by thioflavin-T-binding
assays. (c) Concentration of active enzyme in wtTTR preparations. The concentration of
proteolytically active enzyme was determined by active-site titration with a phosphonate inhibitor.
TTR activity was tested after pre-incubation with a phosphonate inhibitor. Concentration of active
enzyme was determined from the x-axis intercept in the linear range of the plot of residual activity
as a function of inhibitor concentration. Each experiment was performed twice in duplicate.
residue which acts as a general base. From structural analysis
(Figure 5), Glu72 was favoured to be the general base and Glu89
was a less likely candidate. Supporting this hypothesis, mutating
Glu72 abrogated the proteolytic activity of TTR, whereas
mutating Glu89 resulted in a partial reduction in TTR activity.
This latter residue receives two hydrogen bonds from (i) its own
backbone amide, and (ii) the side chain of Thr96′ of a neighbouring
Figure 5 Structure of TTR active site (PDB code 3GRB)
A TTR monomer is represented by its Cα chain (cyan), and a second monomer is displayed in
dark blue. A Zn2 + ligated by the catalytically important residues His88, His90 and Glu92 (red)
is contacting the catalytic water. A second Zn2 + -binding site consisting of general base Glu72,
His31 and Asp74 (orange) is located vicinal to the first site. Glu89 (green) is in hydrogen-bond
contact with Thr96 ′ (blue) of a second TTR monomer which itself also contacts His88. Lys70 is
shown in green. Attractive forces are indicated by broken lines.
second monomer which itself receives a hydrogen bond from His88
of the first monomer (Figure 5). As such, Glu89 fulfils a triple task
in (i) stabilizing the new conformation of rearranged amino acids
74–90, (ii) strengthening the interaction between two monomers
forming a dimer, and (iii) freezing the required conformation of
Thr96′ which keeps His88 in the orientation required to bind Zn2 +
(Figure 5).
Lys70 is a potential hydrogen-bond partner of the general base
Glu72 and could, as such, influence the pKa and conformational
flexibility of this residue. Modelling studies indicated that Lys70
is also in a position to contact a backbone carbonyl oxygen of the
substrate as described previously for Arg203 in thermolysin and
Arg717 in neprilysin [34]. His31 is a second neighbour of Glu72
and also a putative hydrogen-bond partner. To determine the
influence of these two vicinal amino acids of Glu72 on catalytic
activity, we mutated Lys70 to alanine and His31 to glycine. The
results for both mutants confirmed their importance for catalytic
activity with L70A and H31G having only 1.1% and 1.3%
residual activity (Table 1).
A second Zn2 + -binding site in double mutants of TTR
comprising Glu72, His31 and Asp74 [32] is present in close vicinity
to the TTR catalytic site. Its relevance for proteolysis in general
and the role of Asp74 on proteolytic activity in particular were
not obvious which prompted us to generate D74A. Surprisingly,
this mutant suffered only a 2-fold decrease in peptidase activity
(Table 1), thereby indicating that this second Zn2 + -binding site is
not required for proteolytic activity.
In summary, TTR is a mononuclear metallopeptidase with an
inducible active site with His88, His90 and Glu92 serving as Zn2 + -
complexing ligands.
TTR proteolytic activity is unrelated to protein aggregation and
oligomeric state
Several factors, such as the presence of metal ions [6], covalent
modification of Cys10 [7], lowered pH [8] or point mutations
[9], can destabilize the tetrameric TTR structure. To determinate
c© The Authors Journal compilation c© 2012 Biochemical Society
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Figure 6 Correlation between TTR proteolytic activity and protein assembly
and aggregation
(a) Thioflavin-T-binding assays of TTR incubated with the metallopeptidase inhibitors
1,10-phenanthroline and EDTA. (b) Thioflavin-T-binding assays of TTR mutants of the
catalytically active residues. (c) Size-exclusion chromatography of TTR. The elution profile
of wtTTR (WT) and variants C10A/E72A, C10A/H88A, C10A/H90A, C10A/E92A are shown.
Size standards (Stokes radius/molecular mass] elution volumes are indicated: A, catalase
(5.22 nm/232 kDa); B, albumin (3.55 nm/67 kDa); C, ovalbumin (3.05 nm/43 kDa); D,
chymotrypsinogen (2.09 nm/25 kDa); E, ribonuclease (1.64 nm/13.7 kDa). Experiments were
performed in triplicate. *P < 0.05, **P < 0.01.
whether TTR aggregation propensity is increased in the presence
of 1,10-phenanthroline and EDTA or by the TTR mutants of
the active-site residues His88, His90, Glu92 and Glu72, we performed
thioflavin-T-binding assays after protein acidification. In the case
of 1,10-phenanthroline and EDTA, no major effects on wtTTR
aggregation potential were observed (Figure 6a). Regarding the
TTR mutants, no increased aggregation was detected after
the thioflavin-T-binding assay in any of the mutants tested, if
compared with wtTTR (Figure 6b). In accordance with the similar
catalytic efficiency and inhibition profile, TTR C10A presented
an aggregation potential similar to that of wtTTR (Figure 6b).
Interestingly, TTR C10A/H88A, TTR C10A/H90A and TTR
C10A/E92A had a decreased aggregation profile if compared
with either wtTTR or TTR C10A. For TTR C10A/E72A, no
differences in aggregation were detected (Figure 6b). Previous
studies with wtTTR in an acidic environment revealed the
importance of the EF helix–loop region of residues 75–90 in
conformational changes leading to disassembly and subsequent
aggregation of TTR monomers [8]. Interestingly, mutation of
these residues may lead to a decrease in the protein aggregation
potential under acidic conditions. These findings demonstrate that
TTR catalytic activity and protein aggregation are independent
protein properties.
To further investigate possible alterations in the protein
oligomerization state introduced by the mutants described in the
present paper, we subjected wtTTR and all TTR variants used
in the present study to size-exclusion chromatography. All TTR
species eluted in a single highly symmetrical peak (Figure 6c)
with an elution volume of 12.25 ml, corresponding to an estimated
Stokes radius of 3.75 nm. This size is in agreement with the size
(3.20–3.40 nm) reported in the literature for the wtTTR tetramer
[35,36]. No species of greater size were detected in any of the
TTR variants elution profiles.
DISCUSSION
TTR is well known as a transporter of T4 and retinol. In the present
study, we have shown that a change in the secondary structure of
TTR can provide this protein with a complete new functionality.
If it undergoes a partial conformational change, it acquires the
ability to bind Zn2 + and to obtain proteolytic competence. Despite
decades of research on TTR, its proteolytic activity remained
elusive, a fact only explained by (i) the low activity of TTR, and
(ii) the unfavourable equilibrium between proteolytic inactive
and active conformation of wtTTR present at neutral pH. The
structural lability of TTR in the region of amino acids 74–90 is
clearly observable in wtTTR X-ray structures obtained at low pH
(4.0 and 3.5) (PDB codes 3D7P and 3CBR) [8]. These structures
revealed significant changes in this region, proving the existence
of multiple conformations in wtTTR. Recent NMR measurements
[32] performed on wtTTR at pH 7.5 and increasing amounts of
Zn2 + left the vast majority of the protein unaffected in the region
74–90 with only a small part assuming a modified conformation.
The authors concluded that multiple conformations of wtTTR
exist in a dynamic equilibrium with only a rather small fraction
being able to complex Zn2 + . These observations coincide well
with our finding that only about 7% of total tetrameric wtTTR is
in a proteolytic competent conformation at neutral pH.
Interestingly, the very short HXHXE Zn2 + -binding pattern
is novel and was not found in any metallopeptidase known
to date. Since there was no perfect match detected in the
MEROPS database [15], we looked for close analogues and
found a permutated analogue HXEXH in family M22 (O-
sialoglycoprotein peptidase) [37]. Coincidentally, both enzymes
are inhibited by EDTA and 1,10-phenanthroline, but are
insensitive towards phosphoramidon, a well-known inhibitor of
metallopeptidases.
A search of Pfam [38] through 597 TTR sequences revealed
that only in humans and in some non-human primates are all
three amino acids (His88, His90 and Glu92) conserved, whereas
most other organisms lack His90. These findings imply that the
proteolytic activity in TTR was introduced only very late in
evolution possibly to modulate and fine-tune concentrations of
specific substrates.
Interestingly, inhibition of proteolytic activity of TTR by metal
chelators in vitro can be reversed by addition of various divalent
metal ions as already observed for thermolysin [30]. In TTR, Zn2 +
and Mn2 + restored full proteolytic activity, whereas other metals
such as Fe2 + and Co2 + only partially reactivated the enzyme. In
vivo, the plasma concentration of a given metal and the stability
of a metal–TTR complex will define which metal is preferentially
bound to the TTR active site. The apparent dissociation constant
[Kd (app)] of Zn2 + –TTR is 1 μM [6], which suggests that plasma
TTR may circulate as a complex with Zn2 + . However, we cannot
fully exclude that Mn2 + plays a (structural) role different from
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the one assumed for Zn2 + (catalytic), but other metallopeptidases
such as thermolysin [30] or peptide deformylase [31] also tolerate
multiple metal ions in their active site. Nevertheless, Mn2 + , Fe2 +
or Co2 + could not be detected in our TTR preparations.
We determined a kcat/Km value of 408.8 s− 1 · M− 1 for the
active fraction of TTR (7%), which translates to an effective
kcat/Km value of 6.0×103 s− 1 · M− 1. In comparison with other
metallopeptidases, TTR has a lower (although comparable in
some cases) activity than thermolysin (3×104 s− 1 · M− 1) [39],
ACE (angiotensin-converting enzyme) (2.9×105 s− 1 · M− 1) [40]
and neprilysin (3.5×106 s− 1 · M− 1) [41]. Nevertheless, taking into
account the higher plasma concentration of TTR (approximately
5 μM, which corresponds to 350 nM of proteolytically active
TTR) if compared with other typical plasma metallopeptidases
such as ACE (205 pM) [42], one can conclude that TTR
proteolytic activity and its physiological impact should not be
neglected. Moreover, cleavage of prominent substrates such as
apoA-I and Aβ, which are both involved in late-onset diseases
of prime interest such as atherosclerosis and Alzheimer’s disease,
drastically increase the significance of TTR proteolysis. In fact,
we have shown previously that cleavage of apoA-I by TTR might
affect the development of atherosclerosis [20]. In addition, TTR
cleavage of Aβ peptide, identified in vitro, might influence Aβ
deposition [17].
In summary, we have determined that TTR is a metallopeptidase
and identified the residues important for catalytic activity. The
identification of TTR catalytic residues enables the assessment
of the physiological relevance of TTR proteolysis by the
generation of transgenic mice carrying either human wtTTR
or proteolytically inactive human TTR. Furthermore, knowing
the TTR catalytic machinery may be useful for the design and
screening of compounds modulating diseases that are dependent
on TTR-mediated proteolysis such as Alzheimer’s disease and
atherosclerosis.
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Figure S1 ApoA-I cleavage by TTR is blocked by increasing concentrations of EDTA
Figure S2 Cleavage of fluorigenic peptides by wtTTR is inhibited by EDTA
and 1,10-phenanthroline
wtTTR was pre-incubated with different peptidase inhibitors before cleavage of
Abz-YGGRASDQ-EDDnp was determined. *P < 0.0001. Relative fluorescence values were
converted into percentages of residual activity relative to uninhibited controls. Two independent
experiments, each with datasets in duplicate, were performed.
1 These authors contributed equally to this work.
2 These authors contributed equally to this work.
3 To whom correspondence should be addressed (email msousa@ibmc.up.pt).
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Figure S3 wtTTR inhibition by EDTA is reversed by addition of ZnCl2
(a) TTR proteolytic activity was blocked with 1 mM EDTA. Reactivation of TTR with Zn2 + was
tested in either the presence or absence of 1 mM CaCl2. (b) After dialysis, TTR inhibited by EDTA
can be reactivated by Zn2 + . TTR was inhibited with 10 mM EDTA, dialysed and subsequently
reactivated with increasing concentrations of Zn2 + . Representative results are shown and the
experiment was performed at least twice in duplicate. *P < 0.001.
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Figure S4 TTR inhibited by 1,10-phenanthroline can be reactivated by divalent metal ions
TTR was inhibited with 1 mM 1,10-phenanthroline (1,10-phen) and subsequently reactivation was tested with increasing concentrations of Ni2 + (a) and Cu2 + (b).
Figure S5 Structure of the phosphonate inhibitor used for active-site
titration of TTR
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Table S1 MS analysis of full-length TTR or tryptic TTR peptides
For each mutant, both the predicted and the observed mass of the full-length protein or of the tryptic peptide containing the mutated amino acid are shown.
Mutation Peptide Predicted mass (Da) Observed mass (Da)
C10A 1–15 (including initiator methionine) 1603.82 1604.95
H31G 22-35 1414.82 1414.83
K70A 49–76 3083.46 3083.45
C10A/E72A Full-length 13802.50 13804.31
D74A 49–76 3096.53 3096.55
H88A 81–104 2541.28 2541.33
E89A 81–103 2435.25 2435.23
H90A 81–104 2541.28 2541.28
C10A/E92A Full-length 13802.50 13798.51
Table S2 MS analysis of tryptic peptides derived from TTR modified with
Pefabloc SC
Tryptic TTR peptides modified with pefabloc are highlighted in bold. Pefabloc SC modification
corresponds to an increase in mass of 183 Da.
Peptide Predicted mass (Da) Observed mass (Da) Variation
16-34 2021.37 2021.13 − 0.24
16–35 2149.55 2149.29 − 0.26
22–34 1367.59 1367.92 0.33
22–35 1495.77 1495.78 0.01
22–48 2798.13 2797.7 − 0.43
35–48 1449.56 1449.67 0.11
1449.56 1632.95 183.39
36–48 1321.39 1321.51 0.12
49–76 3142.40 3142.46 0.06
3142.40 3325.69 183.29
49–80 3707.04 3706.36 − 0.65
71–80 1269.44 1268.55 − 0.89
77–103 3017.33 3200.24 182.91
81–103 2452.69 2453.05 0.36
104–126 2517.88 2517.81 − 0.07
104–127 2647.00 2646.98 − 0.02
105–126 2361.70 2361.85 0.15
Table S3 MS analysis of tryptic peptides derived from apoA-I modified with
PMSF
The apoA-I tryptic peptide modified with PMSF is highlighted in bold. PMSF modification
corresponds to an increase in mass of 154 Da.
Peptide Predicted mass (Da) Observed mass (Da) Variation
1–10 1226.54 1226.55 0.01
1–12 1453.71 1453.71 0.00
11–27 1878.03 1878.03 0.00
13–27 1650.87 1650.87 0.00
13–40 3032.52 3032.50 − 0.02
24-40 1815.85 1815.85 0.00
46–59 1612.79 1612.78 − 0.01
60–77 2202.12 2202.12 0.00
62–77 1932.93 1932.97 0.04
78–94 2020.99 2021.00 0.01
95–107 1579.85 1579.85 0.00
97–107 1380.72 1380.71 − 0.01
108–116 1283.57 1283.57 0.00
117–131; 119–133 1723.94 1723.94 0.00
119–131 1467.79 1467.78 − 0.01
141–149 1031.52 1031.53 0.01
154–160 781.43 781.43 0.00
161–173 1585.81 1585.82 0.01
189–195 831.44 831.44 0.00
207–215 1012.58 1012.58 0.00
207–226 2224.27 2224.27 0.00
227–238 1386.72 1380.70 − 0.02
1386.72 1540.81 154.09
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